重庆医学
重慶醫學
중경의학
CHONGQING MEDICAL JOURNAL
2015年
2期
186-188,191
,共4页
肖著军%萧著玲%陈金敏%邓飞鸿%许岸高
肖著軍%蕭著玲%陳金敏%鄧飛鴻%許岸高
초저군%소저령%진금민%산비홍%허안고
甲基化%肿瘤%波形蛋白%DNA%进展期腺瘤%甲基化敏感性高分辨率熔解曲线分析
甲基化%腫瘤%波形蛋白%DNA%進展期腺瘤%甲基化敏感性高分辨率鎔解麯線分析
갑기화%종류%파형단백%DNA%진전기선류%갑기화민감성고분변솔용해곡선분석
methylation%neoplasms%vimentin%DNA%advanced adenomas%methylation-sensitive high-resolution melting
目的:评价通过甲基化敏感性高分辨率熔解曲线分析(MS‐HRM)检测粪便中人DNA甲基化筛查大肠癌(CRC)的性能。方法收集合格的新鲜粪便标本82例,其中CRC患者27例(CRC组)、进展期腺瘤(AA)患者25例(AA组)和结肠镜阴性的正常人30例(对照组),在LightCycler480设备上应用MS‐HRM技术检测上述粪便中vimentin基因的甲基化状态,并与粪便潜血试验(FOBT)的诊断性能相比较。结果MS‐HRM在CRC组、AA组和对照组中检测vimentin基因甲基化的阳性率分别为81.5%(22/27),80.0%(20/25)和6.7%(2/30)。FOBT在CRC组、AA组和对照组中的阳性率分别为37.0%(10/27),12.0%(3/25)和3.3%(1/30)。在病例组中,MS‐HRM和FOBT的诊断敏感性分别为80.8%(42/52)和25.0%(13/52),前者显著高于后者(P<0.05);在对照组中两者的诊断特异性分别为93.3%(28/30)和96.7%(29/30),两者差异无统计学意义(P>0.05)。结论在CRC筛查中,MS‐HRM技术检测粪便中vimentin基因甲基化状态的诊断性能明显优于FOBT,具有潜在的应用价值。
目的:評價通過甲基化敏感性高分辨率鎔解麯線分析(MS‐HRM)檢測糞便中人DNA甲基化篩查大腸癌(CRC)的性能。方法收集閤格的新鮮糞便標本82例,其中CRC患者27例(CRC組)、進展期腺瘤(AA)患者25例(AA組)和結腸鏡陰性的正常人30例(對照組),在LightCycler480設備上應用MS‐HRM技術檢測上述糞便中vimentin基因的甲基化狀態,併與糞便潛血試驗(FOBT)的診斷性能相比較。結果MS‐HRM在CRC組、AA組和對照組中檢測vimentin基因甲基化的暘性率分彆為81.5%(22/27),80.0%(20/25)和6.7%(2/30)。FOBT在CRC組、AA組和對照組中的暘性率分彆為37.0%(10/27),12.0%(3/25)和3.3%(1/30)。在病例組中,MS‐HRM和FOBT的診斷敏感性分彆為80.8%(42/52)和25.0%(13/52),前者顯著高于後者(P<0.05);在對照組中兩者的診斷特異性分彆為93.3%(28/30)和96.7%(29/30),兩者差異無統計學意義(P>0.05)。結論在CRC篩查中,MS‐HRM技術檢測糞便中vimentin基因甲基化狀態的診斷性能明顯優于FOBT,具有潛在的應用價值。
목적:평개통과갑기화민감성고분변솔용해곡선분석(MS‐HRM)검측분편중인DNA갑기화사사대장암(CRC)적성능。방법수집합격적신선분편표본82례,기중CRC환자27례(CRC조)、진전기선류(AA)환자25례(AA조)화결장경음성적정상인30례(대조조),재LightCycler480설비상응용MS‐HRM기술검측상술분편중vimentin기인적갑기화상태,병여분편잠혈시험(FOBT)적진단성능상비교。결과MS‐HRM재CRC조、AA조화대조조중검측vimentin기인갑기화적양성솔분별위81.5%(22/27),80.0%(20/25)화6.7%(2/30)。FOBT재CRC조、AA조화대조조중적양성솔분별위37.0%(10/27),12.0%(3/25)화3.3%(1/30)。재병례조중,MS‐HRM화FOBT적진단민감성분별위80.8%(42/52)화25.0%(13/52),전자현저고우후자(P<0.05);재대조조중량자적진단특이성분별위93.3%(28/30)화96.7%(29/30),량자차이무통계학의의(P>0.05)。결론재CRC사사중,MS‐HRM기술검측분편중vimentin기인갑기화상태적진단성능명현우우FOBT,구유잠재적응용개치。
Objective To assess the performance of the methylation‐sensitive high‐resolution melting curve analysis (MS‐HRM analysis) on the detection of the methylation in stool DNA for colorectal cancer screening .Methods Eighty‐two qualified stool samples were collected from 27 patients with colorectal cancer patients (CRC group) ,25 patients with advanced adenomas (AA group) ,and 30 healthy people (control group) .The methylation status of vimentin gene in all of the stool samples was detected by the MS‐HRM analysis on the LightCycler 480 platform .The fecal occult blood test (FOBT) was also used for the same samples . Results The positive rates of the MS‐HRM assay in the CRC group ,AA group ,and control group were 81 .5% (22/27) ,80 .0%(20/25) ,and 6 .7% (2/30) respectively .The positive rates of FOBT in the three groups were 37 .0% (10/27) ,12 .0% (3/25) and 3 .3% (1/30) respectively .The diagnostic sensitivity of the MS‐HRM assay for colorectal cancer and advanced adenomas (80 .8% , 42/52) was significantly higher than that of FOBT (25 .0% ,13/52)(P<0 .05) .No significant difference was found in the diagnos‐tic specificity between the MS‐HRM assay (93 .3% ,28/30) and the FOBT (96 .7% ,29/30) (P>0 .05) .Conclusion MS‐HRM performs better than FOBT and has great application potential in the detection of stool DNA methylation for colorectal cancer screening .